ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

House Appropriations Boosts NIH By $1 Billion In Draft Budget That Cuts Other HHS Programs

September 30, 2011

FDA Grants Accelerated Approval to Imbruvica

November 29, 2013

NCI Programs: Institute Renews 10 Center Grants, Provides Complete Grant List.

January 28, 2005

ACS-Roosevelt Fellows Announced

July 29, 1977

Waxman Subcommittee Hears Support For Cancer Act Renewal

March 7, 1980

New Center Plan Discussed By NAB, Directors Committees

May 4, 1990